×
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545307
Clinical Advances in Hematology & Oncology : H&O;

Sep 23rd, 2019 - Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.|2019||adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,therapy,drug therapy,genetics,therapy,adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545309
Clinical Advances in Hematology & Oncology : H&O;

Sep 23rd, 2019 - Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting.|2019||therapeutic use,drug therapy,therapeutic use,adverse effects,therapeutic use,drug therapy,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,therapeutic use,

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology An...
https://www.ncbi.nlm.nih.gov/pubmed/31545305
Clinical Advances in Hematology & Oncology : H&O; Haverkos B

Sep 22nd, 2019 - Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A hematologist's perspective.|2019|Haverkos B,|

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology An...
https://www.ncbi.nlm.nih.gov/pubmed/31545306
Clinical Advances in Hematology & Oncology : H&O; Geskin LJ

Sep 22nd, 2019 - Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A dermatologist's perspective.|2019|Geskin LJ,|

Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545308
Clinical Advances in Hematology & Oncology : H&O; O'Brien SM

Sep 22nd, 2019 - Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting: commentary.|2019|O'Brien SM,|

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545310
Clinical Advances in Hematology & Oncology : H&O; Mesa RA

Sep 22nd, 2019 - Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting: commentary.|2019|Mesa RA,|

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942175
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation; Holstein SA, Al-Kadhimi Z et. al.

Sep 18th, 2019 - The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discus...

Update on FDA-Approved CAR T-Cell Gene Therapy for B-Cell Lymphomas
https://ascopost.com/issues/september-10-2019/update-on-fda-approved-car-t-cell-gene-therapy-for-b-cell-lymphomas/

Sep 9th, 2019 - Syed Ali Abutalib, MD David L. Porter, MD On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Specifically, this treatment can be used after two or more lines of systemic therapy for diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, primary...

Valoctocogene Roxaparvovec Continues to Improve Bleeding Outcomes in Patients with Hemophilia A
https://www.ashclinicalnews.org/on-location/other-meetings/valoctocogene-roxaparvovec-continues-improve-bleeding-outcomes-patients-hemophilia/

Sep 1st, 2019 - In three-year follow-up results from an ongoing phase I/II study of patients with hemophilia A, valoctocogene roxaparvovec gene therapy significantly reduced annual bleeding rates (ABRs) and increased factor VIII (FVIII) activity levels. Lead author John Pasi, MBChB, PhD, from Barts and the London School of Medicine and Dentistry, presented the findings at the 2019 Congress of the International...

ASH Sickle Cell Initiative Wins Top ASAE Prize, ASH-a-Palooza 2019 Announced, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-sickle-cell-initiative-wins-top-asae-prize-ash-palooza-2019-announced/

Sep 1st, 2019 - ASH Sickle Cell Disease Initiative Wins Top ASAE Prize The American Society of Hematology (ASH) is proud to have been named a 2019 Power of A Summit Award winner for the Society’s multifaceted Sickle Cell Disease (SCD) Initiative. The Power of A Summit Award, given annually by the American Society of Association Executives (ASAE), recognizes the association community’s valuable contributions on...

ABIM: Self-paced MOC pathway under development
https://www.mdedge.com/internalmedicine/article/207353/business-medicine/abim-self-paced-moc-pathway-under-development/page/0/1?channel=27980

Aug 31st, 2019 - Alan Lichtin, MD, chair of the MOC working group for the American Society of Hematology (ASH), said the self-paced pathway is a much-needed option, particularly the immediate feedback on test questions. “For years, ASH has been advocating that ABIM move from the traditional sit-down testing to an alternative form of ‘formative’ assessment that has been adapted by other specialty boards,” Dr.

CMS Expands Access to CAR T-Cell Therapies Nationwide
https://www.ashclinicalnews.org/online-exclusives/cms-expands-access-car-t-cell-therapies-nationwide/

Aug 16th, 2019 - The Centers for Medicare and Medicaid Services (CMS) will now provide “consistent and predictable” nationwide access to chimeric antigen receptor (CAR) T-cell therapies, according to CMS Administrator Seema Verma. This decision comes in the wake of last week’s announcement that CMS was increasing payments for CAR T-cell therapies from 50 percent to 65 percent. Prior to this announcement, Medica...

Highlights in Geriatric Hematology From the ASH Annual Meeting & Exposition
https://ascopost.com/issues/august-10-2019/highlights-in-geriatric-hematology-from-the-ash-annual-meeting-exposition/

Aug 9th, 2019 - GUEST EDITOR Stuart M. Lichtman, MD, FACP, FASCO Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and Professor of Medicine at Weill Cornell Medical College, New York....

ASH Honors Richard Aster, MD, With the Wallace H. Coulter Award for Lifetime Achievement in Hematology
https://ascopost.com/issues/august-10-2019/ash-honors-richard-aster-md/

Aug 9th, 2019 - Richard Aster, MD The American Society of Hematology (ASH) will recognize Richard Aster, MD, of the Medical College of Wisconsin and Versiti Blood Center of Wisconsin in Milwaukee with the 2019 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Aster will be honored for his significant contributions to hematology through research, mentorship, and education throughout his 62-ye...

CMS Increases Payment, Access to CAR T-Cell Therapy
https://www.ashclinicalnews.org/online-exclusives/medicare-increases-payments-car-t-cell-therapy/

Aug 9th, 2019 - The Centers for Medicare and Medicaid Services (CMS) announced two policy changes that should improve access to chimeric antigen receptor (CAR) T-cell therapies: First, the agency issued a final rule that raises payments for new technologies, including CAR T-cell therapies, from 50% to 65%. Next, CMS Administrator Seema Verma said that CMS will now provide “consistent and predictable” nationwid...

Treatment of Pediatric Venous Thromboembolism.
https://doi.org/10.12788/jhm.3246
Journal of Hospital Medicine; Meier KA, Tarango C

Aug 6th, 2019 - American Society of Hematology 2018 Guidelines for the management of venous thromboembolism: treatment of pediatric venous thromboembolism DEVELOPER: The American Society of Hematology multidisciplinary subcommittee RELEASE DATE: November 27, 2018 FUNDING SOURCE: American Society of Hematology PRIOR VERSION: N/A TARGET POPULATION: less than 18 years of age.

ASH Backs Palliative Blood Transfusions During Hospice Care, Announces 2019 Honorific and Mentor Award Recipients, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-backs-palliative-blood-transfusions-hospice-care-announces-2019-honorific-mentor-award-recipients/

Aug 1st, 2019 - ASH Backs the Use of Palliative Blood Transfusions During Hospice Care for Symptom Improvement The American Society of Hematology (ASH) has announced its support of palliative blood transfusions during end-of-life care in a recent policy statement. The Medicare hospice benefit for patients undergoing end-of-life care focuses on maximizing quality of life by providing comfort and support service...

ICYMI: Ibrutinib/rituximab combo improves CLL survival
https://www.mdedge.com/hematology-oncology/article/205472/cll/icymi-ibrutinib/rituximab-combo-improves-cll-survival?channel=59374
Lucas Franki

Jul 31st, 2019 - Patients with previously untreated chronic lymphocytic leukemia (CLL) aged 70 years or younger who received ibrutinib/rituximab therapy experienced significantly greater progression-free survival, compared with those who received standard chemotherapy with fludarabine, cyclophosphamide, and rituximab (89. 4% vs.

Tumour flare reaction in cancer treatments: a comprehensive literature review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749970
Anti-cancer Drugs; Taleb B A

Jul 27th, 2019 - In the past decade, tumour flare reaction (TFR) was considered as a new side effect associated with immunomodulatory agents (IMiDs) and as a condition of chronic lymphocytic leukaemia (CLL). However, this phenomenon is also observed with immune checkpoint inhibitors in solid tumours. It is still poorly understood and its incidence is underestimated. TFR has been associated with morbidity, there...

FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
https://ascopost.com/issues/july-25-2019/fda-approves-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-multiple-myeloma/

Jul 24th, 2019 - On June 27, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The application received approval through the FDA’s Real-Time Oncology Review pilot program. The approval is based on results f...